$ARIA Recent Headlines Apple closes lower; B. of A. rises

New Post Public Reply Private Reply Replies (0) Message Board

Jan 13, 2014 at 12:53 PM

$ARIA Recent Headlines

Apple closes lower; B. of A. rises on analyst call 4:15 p.m. Jan. 2, 2014 - Wallace Witkowski
Apple gains on China Mobile deal; homebuilders rally 3:33 p.m. Dec. 23, 2013 - Wallace Witkowski
Suspension is lifted for Ariad's leukemia drug 6:33 a.m. Dec. 23, 2013 - MarketWatch.com
J.C. Penney and more of the year's most profitable shorts 3:23 p.m. Dec. 9, 2013 - blogs.marketwatch.com
Hewlett-Packard, a cyclical green light and why silver is in trouble 8:50 a.m. Nov. 26, 2013 - Shawn Langlois
Ariad takes another pounding after leukemia treatment is pulled 12:14 p.m. Oct. 31, 2013 - Russ Britt
H-P has best day in four months on upbeat outlook 3:34 p.m. Oct. 9, 2013 - Sue Chang
Ariad plummets 70% after drug test patients have serious clotting issues 10:38 a.m. Oct. 9, 2013 - Russ Britt
FDA places partial hold on Ariad's Iclusig trials 7:16 a.m. Oct. 9, 2013 - MarketWatch.com
Dan Loeb makes bet on Disney 7:06 p.m. Aug. 14, 2013 - David Benoit
Onyx share surge lifts several boats in biotech harbor, including ETFs 10:33 a.m. July 1, 2013 - Russ Britt
SAC Capital Advisors likes this pharma stock 3:24 p.m. April 18, 2013 - Insider Monkey
Ariad Pharma up 6% to $20.09 10:35 a.m. Dec. 17, 2012 - Steve Gelsi
FDA OKs Iclusig to treat rare types of leukemia 1:06 p.m. Dec. 14, 2012 - MarketWatch.com
Stocks: Investors play the waiting game 8:53 a.m. Dec. 11, 2012 - The Trading Deck
12 biotech stocks hit 52-week highs 2:43 p.m. July 27, 2012 - Val Brickates Kennedy
Three rules for short selling 12:01 a.m. Feb. 2, 2012 - The Trading Deck
Stocks to watch Wednesday: C.R. Bard, Papa John’s 6:52 a.m. Dec. 21, 2011 - MarketWatch
Don't be a fan when investing 8:26 a.m. Dec. 20, 2011 - The Trading Deck
Drug stocks move higher in late trading 2:26 p.m. March 24, 2011 - Val Brickates Kennedy

UPDATE: JMP Securities Reiterates Coverage on ARIAD Pharmaceuticals, Sees Market Share Regain 10:51 a.m. Today - benzinga.com
Is A Short Squeeze Ahead for Ariad Pharmaceuticals, Inc. (ARIA)? - Tale of the Tape 7:29 a.m. Today - Zacks.com
Biotech Stock Mailbag: NeoStem, MannKind, Inovio 6:00 a.m. Jan. 10, 2014 - TheStreet.com
Some Stock Ideas For January 2014 9:28 a.m. Jan. 8, 2014 - Seeking Alpha
Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Laggard 5:01 p.m. Jan. 7, 2014 - TheStreet.com
ARIAD to Present at JPM Conference - Analyst Blog 6:00 p.m. Jan. 6, 2014 - Zacks.com
UPDATE: Ariad Pharmaceuticals Downgraded by Citigroup 10:42 a.m. Jan. 6, 2014 - benzinga.com
Citi negative on Sarepta, Ariad for 2014, shares slide 8:21 a.m. Jan. 6, 2014 - Seeking Alpha
Top Analyst Downgrades, Stocks to Sell: Apple, Twitter, First Solar and More 7:53 a.m. Jan. 6, 2014 - 247WallSt.com
Benzinga's Top #PreMarket Losers 7:19 a.m. Jan. 6, 2014 - benzinga.com
A Strange Mix of Action 4:44 p.m. Jan. 3, 2014 - RealMoney.com
Patience and Prudence 10:39 a.m. Jan. 3, 2014 - RealMoney.com
Biotech Stock Mailbag: Inovio, Chelsea, Exelixis, Ariad, ImmunoCellular 8:00 a.m. Jan. 3, 2014 - TheStreet.com
Ariad rallies, company to present at conference 1:37 p.m. Jan. 2, 2014 - Seeking Alpha
Benzinga's Top #PreMarket Gainers 7:12 a.m. Jan. 2, 2014 - benzinga.com
ARIAD to Present at JP Morgan Healthcare Conference on Tuesday, January 14 at 6:00 PM ET 6:39 a.m. Jan. 2, 2014 - benzinga.com
Can The Uptrend Continue for Ariad Pharmaceuticals, Inc. (ARIA)? - Tale of the Tape 8:41 a.m. Dec. 31, 2013 - Zacks.com
Mid-Day Market Update: US Markets Turn Lower; Twitter Shares Fall On Analyst Downgrade 12:46 p.m. Dec. 27, 2013 - benzinga.com
Mid-Morning Market Update: Markets Mostly Higher; Textron To Acquire Beechcraft For $1.4B 10:19 a.m. Dec. 27, 2013 - benzinga.com
Ariad Revenue Boosted by Iclusig 12:45 a.m. Dec. 27, 2013 - Barrons.com

Biologics Selected by ARIAD to Be the Exclusive Specialty Pharmacy Provider for Iclusig (ponatinib) 7:30 a.m. Today - BusinessWire - BZX
Notable Buzzers: Ariad Pharmaceuticals, Twitter Inc, Facebook Inc, Qihoo 360 Technology 11:10 a.m. Jan. 8, 2014 - ACCESSWIRE
Conferences, Completed Acquisitions, and Stock Price Movements - Research Report on Ariad, Salix, Molina, Mednax, and Merrimack 8:00 a.m. Jan. 7, 2014 - PR Newswire
Morning Buzzers: Apple Inc, Plug Power Inc, Ariad Pharmaceuticals, Biodel Inc 10:01 a.m. Jan. 3, 2014 - ACCESSWIRE
ARIAD to Present at the 32nd Annual J.P. Morgan Healthcare Conference 7:34 a.m. Jan. 2, 2014 - BusinessWire
FDA Approvals, Stock Price Movements, and Acquisitions - Research Report on ARIAD, Gentium, Salix Pharmaceuticals, NPS Pharmaceuticals, and MEDNAX 8:00 a.m. Dec. 25, 2013 - PR Newswire
Insider Catalyst Report: Ariad Pharmaceuticals, Advanced Micro Devices, Petroleo Brasileiro Petrobras, Endeavor IP Inc 10:32 a.m. Dec. 23, 2013 - ACCESSWIRE
Stock Price Updates, Executive Appointments, Acquisitions, Orphan Drug Designations, and Preclinical Developments - Research Report on Ariad, Halozyme, DepoMed, Omeros, and BioCryst 8:00 a.m. Dec. 23, 2013 - PR Newswire
Technical Research on Equities: Ariad Pharma, MannKind, Galena Biopharma, and Novavax 8:00 a.m. Dec. 23, 2013 - PR Newswire
Bullish Trend Analysis: Ariad Pharmaceuticals, Federal Home Loan Mortgage Corp, NQ Mobile Inc, Micron Technology 11:02 a.m. Dec. 20, 2013 - ACCESSWIRE
ARIAD Announces U.S. Resumption of Marketing and Commercial Distribution of Iclusig (ponatinib) in Refractory Philadelphia-Positive Leukemias 10:10 a.m. Dec. 20, 2013 - BusinessWire
Sector PE Trend, Return On Asset, and Consensus Earnings Forecast for Facebook, Ford Motor, Ariad Pharmaceuticals, Rite Aid, Sirius XM, and Tesla Motors 9:00 a.m. Dec. 20, 2013 - PR Newswire
Traders Buzz: Oracle Corporation, General Electric Company, Ariad Pharmaceuticals, Vertex Pharmaceuticals Incorporated 10:40 a.m. Dec. 19, 2013 - ACCESSWIRE
Published Data, Stock Price Movements, and FDA Approvals - Research Report on Johnson & Johnson, Ariad Pharmaceuticals, PerkinElmer, BD, and Sanofi 8:00 a.m. Dec. 13, 2013 - PR Newswire
Morning Buzz: Facebook Inc, BlackBerry Ltd, Ariad Pharmaceuticals, Nokia Corporation 11:19 a.m. Dec. 12, 2013 - ACCESSWIRE
Stocks Of The Day: Alpha Natural Resources, Apple Inc, Ariad Pharmaceuticals, Verizon Communications 10:40 a.m. Dec. 9, 2013 - ACCESSWIRE
Faruqi & Faruqi, LLP Files Class Action Lawsuit Against ARIAD Pharmaceuticals, Inc. (ARIA) 8:00 p.m. Dec. 6, 2013 - PR Newswire
UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Against ARIAD Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ARIA 6:11 p.m. Dec. 5, 2013 - PR Newswire
Blue Chip Stock News: Ariad Pharmaceuticals, Citigroup Inc, Arena Pharmaceuticals, Market Vectors Gold Miners 9:45 a.m. Dec. 5, 2013 - ACCESSWIRE
Stock Price Movements, Campaigns, New Clinical Studies, and Approvals- Research Report on Actavis, Ariad Pharmaceuticals, DaVita, Celldex, and WellCare 8:00 a.m. Dec. 5, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Miracle League Marks Two Decades with Big Fundraising Win

A Double Decade Celebration of Dream and Dedication The Miracle League of the Triangle sure knows how to throw a party—for them, it's not just a gala; it's a testament to two decades of turning dreams into reality. On October 13th, over 300 guests gathered at the Angus Barn Pavilion in Cary, NC, proving that passion for inclusive baseball is just as alive as it was 20...

Extra Mile Day: 18 Years of Honoring Unsung Heroes

Pedaling for Purpose: A Journey That Sparked a Movement What started as a lone journey across America's roads has turned into a celebrated movement to honor those who often go unnoticed. Back in 2009, Shawn Anderson embarked on an unusual journey. Armed only with a bicycle and determination, he pedaled from San Francisco to Boston—over 4,000 miles in just 90 days. It...

Fidelis Care Opens $120K Workforce Grants for Aid

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Nelson Peltz Doubles Down: Burgers or Pucks?

Mixing Hockey and Hamburgers: The Peltz Way You'd think a guy like Nelson Peltz wouldn't be juggling hockey sticks and hamburgers at the same time, but here we are. The man, a mogul of sorts with Trian Fund Management, is hopping onto a board seat with a New York hockey company and, oh, by the way, throwing a non-binding $7.35-a-share cash proposal to snatch up Wendy's, a...

Jamaica's Tourism Rebounds Post-Hurricane Challenges

Weathering the Storm: A New Chapter for Jamaica It's been nearly a year since Hurricane Melissa hit, and Jamaica is proving that it won't be pushed around by nature's whims. The island's tourism industry, once battered, is now showing remarkable resilience. With hotels and villas reopening and shaking off the dust, it's safe to say Jamaica is back on its feet, and it's...

Virginia Cancer Specialists: Leaders in Trusted Cancer Care

Decades of Trust in Cancer Care Virginia Cancer Specialists isn't just another name in the sea of healthcare providers. That pride they're feeling? Well, they've got every right to it. Just slapped their physicians' names all over the latest Washingtonian's Top Doctors list for 2026. And this isn’t some under-the-table handshake deal. No, this list is shaped by peer...

Genefluence Launches Rapid UTI PCR Test at Chelsea Hospital

There's a fresh breeze blowing through the dusty corridors of healthcare, shaking things up for the better. You see, Genefluence, the brainchild of Professor Chris Toumazou, isn't just throwing a bunch of tech jargon around—it's setting the stage for a much-needed shake-up in how we handle urinary tract infections (UTIs) and, believe me, it couldn’t have come sooner....

Unicycive Faces Legal Heat: Shareholder Lawsuit Looms

The Unicycive Landslide: What Went Down? Investors, buckle up. Unicycive Therapeutics Inc. (NASDAQ: UNCY) finds itself deep in the muck of a securities class action. Chief honchos, CEO Shalabh Gupta and CFO John Townsend, are taking the heat for allegedly controlling company disclosures that led shareholders to believe in non-existent progress with their third-party...

Infoya Surges with 665% Growth, Wins Fast 50 Spot

From Humble Beginnings to High Achiever Alright, let's touch base on Canada's tech landscape for a moment. Infoya's leap into Deloitte's 2026 Technology Fast 50 isn't just a pat on the back—it's a flashing neon sign of what raw ambition mixed with a pinch of AI can cook up for you. They've banked a whopping 665% revenue growth from 2022 to 2025. Not bad for a company...

Heritage Wines Meet Non-Alcoholic Trend: New Deal

Wine Industry Shifts Gears Well, here's a twist that might just shake up the wine racks. C. Mondavi & Family, from the historic Charles Krug estate, is aligning with Missing Thorn—a name gaining traction in the non-alcoholic wine scene. It’s a move that not only raises eyebrows but could also expand your wine-tasting options come your next sober night out. So what...